Cancer cells exhibit distinct metabolic phenotypes compared to normal cells, which has spurred interest in their specific biochemical pathways. The CLIC1-PKM2 axis is positioned at the nexus of crucial metabolic processes, where chloride intracellular channel 1 (CLIC1) interacts with pyruvate kinase isozyme M2 (PKM2). This study meticulously elucidates how this interaction enhances the glycolytic process, allowing cancer cells to thrive under conditions of limited oxygen, a phenomenon known as the Warburg effect. By harnessing these findings, future therapies could aim to disrupt this axis, potentially starving tumor cells of the energy they require to grow and spread.

The findings from this research are particularly significant in the context of gastric cancer, a malignancy notoriously associated with poor prognosis and limited treatment options. The team’s investigations revealed that elevated levels of CLIC1 correspond with aggressive tumor behavior and poor patient outcomes. As such, it raises the tantalizing prospect that CLIC1 could serve as a robust biomarker for gastric cancer, aiding in both diagnosis and the monitoring of disease progression. More importantly, targeting this marker could lead to innovative treatment strategies that enhance therapeutic efficacy.

It’s noteworthy that the classical view of tumor metabolism is being challenged by this new paradigm, with an emphasis on how specific metabolic pathways facilitate tumor growth and survival. The interaction between CLIC1 and PKM2 exemplifies how cancer cells can adapt their metabolism to exploit alternative energy pathways. The study’s authors provide a thorough analysis of this interaction, examining enzymatic activities and downstream metabolic consequences. Understanding these mechanisms at an in-depth biochemical level paves the way for the development of novel inhibitors that could thwart cancer cell proliferation.

Moreover, the study compels us to reconsider existing therapeutic approaches. Current treatments for gastric cancer, such as chemotherapy and targeted therapy, have shown limited successes. By integrating metabolic reprogramming into our therapeutic arsenal, clinicians could personalize treatment options that more effectively combat the unique metabolic needs of gastric tumors. Furthermore, with a focus on the CLIC1-PKM2 axis, researchers may uncover additional vulnerabilities within the metabolic networks of gastric cancer cells that were previously overlooked.

The potential integration of metabolic inhibitors into treatment regimens could herald a new era of precision medicine for gastric cancer patients. By targeting the molecular machinations that drive tumor growth, oncologists may not only enhance the efficacy of existing therapies but may also extend survival rates and improve quality of life. This focus on the metabolic dependencies of cancer cells underscores a paradigm shift in how we approach treatment and opens avenues for innovative research that could lead to breakthrough therapies.

The research also highlights the importance of collaborative efforts across disciplines. The complexities of cancer demand integrative approaches that combine biochemistry, oncology, and molecular biology. Multi-institutional collaborations could facilitate the rapid translation of laboratory findings into clinical applications. The convergence of these fields is vital to unraveling the intricate metabolic networks that sustain cancer, thus accelerating the development of actionable therapies that can combat this disease effectively.

In summary, the investigators provide a compelling case for the involvement of the CLIC1-PKM2 axis in the metabolic rewiring of gastric cancer cells. Their results suggest that by targeting this axis, it may be possible to hinder cancer progression and offer patients new hope for effective treatment. The implications of this research extend beyond the realm of gastroenterology, potentially informing treatment strategies for other malignancies where similar metabolic alterations are observed.

As research efforts continue to unravel the complexities of cancer metabolism, it will be essential to remain vigilant for new therapeutic targets. This study serves as a stepping stone towards understanding metabolic dysregulation in cancer cells, reinforcing the notion that manipulating metabolic pathways could yield significant benefits in cancer therapy. The potential interaction of the CLIC1-PKM2 axis with other metabolic and signaling pathways provides a rich ground for future exploration that could further elucidate the multifaceted nature of gastric cancer.

The immediate future appears promising for those affected by gastric cancer, thanks to the relentless pursuit of researchers dedicated to discovering transformative pathways in cancer metabolism. As we continue to grapple with the challenges posed by this aggressive disease, insights from studies like this one may illuminate new paths forward, enhancing therapeutic strategies and patient outcomes in ways we are only beginning to comprehend. The collaboration between basic and clinical researchers will undoubtedly be imperative in translating these laboratory findings into groundbreaking clinical applications.

In conclusion, the research conducted by Yang, J., Yu, Z., and Feng, Y. lays crucial groundwork for our understanding of the metabolic mechanisms underpinning gastric cancer. The CLIC1-PKM2 axis emerges as a critical player in the orchestration of glycolytic metabolism, substantiating its potential as a target for innovative therapeutic development. This pioneering work opens a new chapter in the ongoing battle against gastric cancer, inspiring hope in patients and clinicians alike.

Subject of Research: Exploration of the CLIC1-PKM2 axis and its role in glycolytic metabolism in gastric cancer progression.

Article Title: The CLIC1-PKM2 axis orchestrates glycolytic metabolism to accelerate gastric cancer progression.

Article References:

Yang, J., Yu, Z., Feng, Y. et al. The CLIC1-PKM2 axis orchestrates glycolytic metabolism to accelerate gastric cancer progression.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07463-6

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07463-6

Keywords: gastric cancer, CLIC1-PKM2 axis, glycolytic metabolism, cancer progression, metabolic pathways.

Cancer cells notoriously adapt their metabolism to meet the high energy and biosynthesis demands of uncontrolled growth. One hallmark of this adaptation is the preferential use of glycolysis, a quick but inefficient sugar breakdown pathway that generates metabolic intermediates essential for cell division. The UCLA team’s research uniquely identifies IGF2BP3 as a key modulator that not only modulates RNA but drastically shifts leukemia cells toward this glycolytic metabolism, highlighting a dual role that redefines conventional views of cellular regulation in cancer biology.

Professor Dinesh Rao, leading the study at UCLA’s David Geffen School of Medicine, emphasizes the surprising breadth of IGF2BP3’s influence, stating that its contribution to metabolic remodeling was unexpected and highly significant. This novel insight uncovers an intricate interplay between gene expression control at the RNA level and energy metabolism, processes long assumed to operate separately in cancer cells. The discovery implies that impeding IGF2BP3 could simultaneously halt the metabolic fueling and protein synthesis machinery that leukemia cells exploit to aggressively proliferate.

IGF2BP3 belongs to a family of RNA-binding proteins typically active only in early human development, after which their expression dramatically decreases. However, in various malignancies such as leukemia, brain tumors, sarcomas, and breast cancers, this protein mysteriously reactivates, driving oncogenic processes. The UCLA group’s prior work demonstrated that IGF2BP3 is indispensable for a highly aggressive subtype of pediatric acute lymphoblastic leukemia, with knockout mouse models resistant to leukemia development without evident health defects. These findings suggested IGF2BP3’s unique role in cancer, spurring further exploration of its impact on cellular energetics.

To interrogate IGF2BP3’s metabolic role, the researchers utilized the sophisticated Seahorse assay technology. This method measures oxygen consumption and extracellular acidification rates, effectively placing cells on a metabolic treadmill to analyze how they utilize energy. Remarkably, leukemia cells deprived of IGF2BP3 showed a profound reduction in glycolysis, indicating that the protein favors rapid sugar catabolism despite its inefficiency in total ATP generation. This metabolic shift ensures a supply of anabolic precursors critical for rapid cell growth, illustrating how IGF2BP3 orchestrates adaptive metabolism tailored to leukemia cells’ survival.

Further metabolic tracing revealed that without IGF2BP3, levels of S-adenosyl methionine (SAM), a universal methyl donor for RNA modifications, plummeted. As RNA methylation is vital for post-transcriptional gene regulation and proper protein synthesis, this finding highlights an elegant feedback loop where IGF2BP3-dependent metabolism affects RNA regulation through epigenetic-like chemical tagging. The diminished RNA methylation marks in IGF2BP3-deficient cells elucidate a previously unrecognized axis linking metabolism directly to RNA function, reshaping the conceptual framework of cancer cell biology.

To validate these molecular insights in vivo, the team engineered mice lacking the IGF2BP3 gene and subsequently introduced the human IGF2BP3 gene. This reintroduction restored the disrupted metabolic and RNA regulatory processes, unequivocally confirming IGF2BP3’s central role in driving the pathological state. This animal model experiment underscores the therapeutic potential of targeting IGF2BP3, as its absence impedes leukemia development while sparing healthy tissue function, making it an attractive candidate for anti-cancer drug development.

Postdoctoral scholar Dr. Gunjan Sharma, a pivotal member of the research team, described the multistep cascade initiated by IGF2BP3 as a “chain reaction.” The protein’s absence reverberated through cellular systems, not only attenuating energy utilization but also altering the chemical and epigenetic landscape governing RNA. This discovery provides a mechanistic explanation for how leukemia cells co-opt metabolic and RNA regulatory networks to maintain their malignant state, offering a holistic target instead of isolated pathways that often lead to drug resistance.

The study’s findings signify that the glycolytic pathway favored by leukemia cells via IGF2BP3 is chosen not for energy efficiency but for its biosynthetic advantage. The swift generation of metabolic intermediates supplies essential building blocks like nucleotides and amino acids, while SAM-driven RNA modifications ensure robust translation of oncogenic proteins. This metabolic rewiring crafts a cancer-specific survival niche, dramatically differentiating malignant cells from their normal counterparts and revealing vulnerabilities that could be exploited therapeutically.

IGF2BP3 thus functions as a molecular architect, simultaneously reshaping energy metabolism and RNA modification machineries to produce an optimal environment for cancer cell endurance and expansion. By coordinating these complex networks, the protein secures leukemia cells’ dominance in hostile conditions that would otherwise suppress normal cell proliferation. This dual regulatory role distinguishes IGF2BP3 from traditional cancer targets that typically affect singular pathways.

While this research filtered through the lens of leukemia, the implications are far-reaching. Similar metabolic and RNA regulatory strategies may be operational across diverse cancer types, including solid tumors like breast cancer and brain cancers where IGF2BP3 is aberrantly expressed. Therefore, insights gained here could inspire broad-spectrum therapies targeting metabolic and post-transcriptional regulatory hubs critical to malignant growth, potentially revolutionizing oncology treatment paradigms.

Moreover, the researchers propose that heightened expression of IGF2BP3 may serve as a diagnostic biomarker, pinpointing cancers that depend on these integrated pathways and identifying patients likely to benefit from therapies aimed at disrupting IGF2BP3’s function or the metabolic networks it controls. This stratification could enhance precision medicine efforts and optimize clinical outcomes in cancer care.

Currently, Rao’s laboratory is advancing small-molecule inhibitors designed to block IGF2BP3 activity. The most effective therapeutic strategies may combine these molecular inhibitors with drugs that directly interfere with cancer metabolism, creating a one-two punch that starves cancer cells energetically and impairs their RNA regulatory machinery. Such combination therapies hold promise for overcoming resistance mechanisms and achieving durable remissions in patients with aggressive leukemia and possibly other IGF2BP3-driven tumors.

The multidisciplinary team contributing to this study spans expertise in molecular biology, metabolism, and translational medicine, including researchers from UCLA and the University of California, Santa Cruz. Supported by grants from the National Institutes of Health and the California Institute for Regenerative Medicine, this collaboration underscores the importance of integrated scientific approaches in unraveling complex cancer biology and moving toward innovative therapies that could save countless lives.

Subject of Research:
Leukemia cell metabolism and RNA regulation linked by IGF2BP3 protein

Article Title:
IGF2BP3: A Master Regulator Linking Metabolic Reprogramming and RNA Modification in Leukemia

News Publication Date:
2025

Web References:
http://dx.doi.org/10.1016/j.celrep.2025.116330

Keywords:
Leukemia, RNA, Metabolism, Cancer, Blood cancer, Cancer cells, Cancer research, Oncology

Colon cancer remains among the most lethal malignancies worldwide, largely due to its complex pathophysiology and resistance to conventional treatments. The newly identified protein, ENTR1, also recognized as Serologically Defined Colon Cancer Antigen 3 (SDCCAG3), has caught the attention of researchers due to its integral role in protein trafficking within the cell. ENTR1’s function in endosomal transport was known, but its implication in cancer metabolism had not been previously explored with such depth. This study bridges that critical knowledge gap, providing compelling evidence that ENTR1 modulates tumor growth by orchestrating glycolytic pathways.

Energy metabolism reprogramming, especially enhanced glycolysis or the “Warburg effect,” is a hallmark of cancer cells, enabling rapid proliferation even in oxygen-rich environments. The research team embarked on a comprehensive investigation, analyzing ENTR1 expression patterns across normal and tumor tissues using extensive clinical datasets. The data revealed consistent upregulation of ENTR1 in a variety of tumors, including colon cancer, hinting at its possible oncogenic role. By leveraging Mendelian randomization, a sophisticated genetic epidemiology method, they further unraveled a causal relationship implicating ENTR1 as a driver of colon cancer susceptibility.

Beyond observational data, the study harnessed the power of machine learning algorithms combined with metabolite-based Mendelian randomization to dissect the metabolic consequences of ENTR1 dysregulation. These high-throughput computational techniques illuminated a nexus between heightened ENTR1 activity and augmented glycolytic flux in cancer cells. This metabolic reprogramming fuels the aggressive growth patterns observed in colon tumors, pinpointing ENTR1 as a critical molecular switch that toggles energy pathways in favor of malignancy.

Validating these computational findings, in vitro experiments utilizing the HCT-116 colon cancer cell line demonstrated that knocking out ENTR1 expression markedly diminishes cellular proliferation. This perturbation also led to a significant reduction in the expression of key glycolytic enzymes, underscoring the protein’s direct influence on metabolic machinery. Through this functional validation, the study not only confirms ENTR1’s oncogenic role but also highlights its potential as a strategic target to disrupt cancer metabolism therapeutically.

The research design, marked by an integrative approach spanning clinical data mining, genetic epidemiology, machine learning, and bench experiments, exemplifies the cutting-edge methodology necessary to tackle complex cancer biology questions today. It underscores the utility of Mendelian randomization not only to establish causality but to identify metabolic pathways that could be exploited for intervention. ENTR1’s role as a metabolic regulator therefore represents a paradigm shift in understanding how intracellular trafficking proteins may influence tumor energetics and growth.

Intriguingly, the study’s findings resonate with the growing body of literature linking aberrant intracellular trafficking and endosomal dynamics to cancer progression. ENTR1, situated at this intersection, may coordinate not just metabolic enzyme expression but also the subcellular localization and function of signaling molecules pivotal for tumor survival. Such multifaceted roles emphasize the necessity of exploring ENTR1 within broader cellular contexts, which may unveil additional vulnerabilities in cancer cells.

Translational implications of this discovery are profound. By targeting ENTR1, researchers envision novel therapeutic strategies that could selectively impair cancer cell metabolism without affecting normal cells. Given the heightened glycolytic dependencies of tumors, inhibiting ENTR1 might starve cancer cells of their primary energy source, thereby halting growth and possibly sensitizing tumors to existing treatments. The prospect of targeting a regulator upstream of metabolic enzymes adds a new dimension to cancer metabolic therapies.

Moreover, the study sheds light on the prognostic potential of ENTR1 expression levels. Elevated ENTR1 could serve as a biomarker to identify patients with more aggressive or treatment-resistant colon cancer phenotypes. This would enable clinicians to tailor therapies more effectively and monitor disease progression with greater precision. Integrating ENTR1 assessment into diagnostic workflows could refine patient stratification and therapeutic decision-making.

Despite the exciting revelations, the authors acknowledge the necessity for further research to delineate the exact molecular mechanisms through which ENTR1 controls glycolytic enzyme expression. Investigating its interactions with transcriptional regulators or signaling pathways central to metabolism may provide deeper insights. Animal model studies are also warranted to assess the systemic effects and therapeutic potential of ENTR1 modulation in vivo.

In addition to colon cancer, the upregulation of ENTR1 observed across multiple tumor types hints at a broader oncogenic role. Future expansive studies across diverse cancers could establish whether ENTR1-driven metabolic rewiring is a common thread among malignancies, suggesting wide applicability of ENTR1-targeted treatments. Cross-cancer comparisons might also reveal tumor-type-specific differences in ENTR1 function and regulatory networks.

This research exemplifies the power of integrative, multidisciplinary approaches in unraveling cancer biology’s intricacies. By combining computational genetics, metabolomics, and molecular biology, the team has crafted a compelling narrative of how a trafficking regulator affects the metabolic fate of cancer cells, reinforcing the idea that metabolism and intracellular transport are intertwined drivers of oncogenesis.

As cancer research continues to navigate the complex interplay between genetics, metabolism, and cellular dynamics, proteins like ENTR1 offer promising targets that transcend traditional therapeutic categories. The potential to manipulate energy supply at the molecular transport level could revolutionize treatment paradigms, shifting the focus from symptom management to metabolic disruption.

Importantly, these findings come at a crucial time when the oncology field is intensely exploring metabolism-based therapies. The identification of ENTR1’s role aligns with efforts to find novel vulnerabilities in cancer’s metabolic network, reinforcing the critical importance of studying non-canonical regulators that orchestrate tumor energetics beyond classic metabolic enzymes.

Looking ahead, partnerships between academic researchers, pharmaceutical developers, and clinical practitioners will be essential to translate these findings into effective treatments. Drug development efforts targeting ENTR1 could pave the way for a new class of therapeutics that impair tumor metabolism with high specificity and minimal toxicity.

In summary, this study offers a transformative insight into how ENTR1 promotes colon cancer progression by modulating glycolysis and energy metabolism. By revealing ENTR1 as a crucial metabolic regulator and oncogenic driver, the research paves the way for innovative therapeutic strategies that exploit metabolic dependencies in cancer. It highlights the untapped potential of intracellular trafficking proteins as key players in cancer biology and treatment, marking a significant milestone in the ongoing battle against colon cancer.

Subject of Research: The role of ENTR1 in colon cancer progression through regulation of energy metabolism and glycolysis.

Article Title: ENTR1 affects the progression of colon cancer by regulating energy metabolism under the influence of glycolysis.

Article References:
Ma, A., Zhai, C., He, Q. et al. ENTR1 affects the progression of colon cancer by regulating energy metabolism under the influence of glycolysis. BMC Cancer 25, 992 (2025). https://doi.org/10.1186/s12885-025-14412-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14412-5